ArticleBMJ (Clinical research ed.)2000
Cost utility analysis of sildenafil compared with papaverine-phentolamine injections.
Article in BMJ (Clinical research ed.), 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- The effects and safety of testosterone replacement therapy for men with hypogonadism: the TestES evidence synthesis and economic evaluation.Health technology assessment (Winchester, England) · 2024Pooled it
- Adherence of pharmacoeconomic studies to national guidelines in the Netherlands.Pharmacy world & science : PWS · 2005Pooled it
- Prolonged conservative treatment or 'early' surgery in sciatica caused by a lumbar disc herniation: rationale and design of a randomized trial [ISRCT 26872154].BMC musculoskeletal disorders · 2005Trial
- A cost-utility analysis of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction.The European journal of health economics : HEPAC : health economics in prevention and care · 2020Article
- Erectile dysfunction management after failed phosphodiesterase-5-inhibitor trial: a cost-effectiveness analysis.Translational andrology and urology · 2019Article
- One of these things is not like the others: the idea of precedence in health technology assessment and coverage decisions.The Milbank quarterly · 2005Review
- Cost implications of sexual dysfunction: the female picture.International journal of impotence research · 2004Article
- Epidemiology of erectile dysfunction.International journal of impotence research · 2003Article
- Cost effectiveness analysis in health care: contraindications.BMJ (Clinical research ed.) · 2002Article
- Clinical update on sildenafil citrate.British journal of clinical pharmacology · 2002Review
- The cost to the United Kingdom National Health Service of managing erectile dysfunction: the impact of sildenafil and prescribing restrictions.PharmacoEconomics · 2002Article
- Health-related quality of life research and the capability approach of Amartya Sen.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2001Article
- Valuing the effects of sildenafil in erectile dysfunction. Strong assumptions are required to generate a QALY value.BMJ (Clinical research ed.) · 2000Article
- Cost effectiveness of sildenafil calls for political discussion.BMJ (Clinical research ed.)Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare the cost effectiveness of sildenafil and papaverine-phentolamine injections for treating erectile dysfunction.
designCost utility analysis comparing treatment with sildenafil (allowing a switch to injection therapy) and treatment with papaverine-phentolamine (no switch allowed). Costs and effects were estimated from the societal perspective. Using time trade-off, a sample of the general public (n=169) valued health states relating to erectile dysfunction. These values were used to estimated health related quality of life by converting the clinical outcomes of a trial into quality adjusted life years (QALYs).
participants169 residents of Rotterdam.
main outcome measuresCost per quality adjusted life year.
resultsParticipants thought that erectile dysfunction limits quality of life considerably: the mean utility gain attributable to sildenafil is 0.11. Overall, treatment with sildenafil gained more QALYs, but the total costs were higher. The incremental cost effectiveness ratio for the introduction of sildenafil was pound sterling 3639 in the first year and fell in following years. Doubling the frequency of use of sildenafil almost doubled the cost per additional QALY.
conclusionsTreatment with sildenafil is cost effective. When considering funding sildenafil, healthcare systems should take into account that the frequency of use affects cost effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.